Clene Inc.
NASDAQ:CLNNBiotechnology
+$0.08 today
- Market cap
- $52.70M
- Beta
- 0.92
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$2.88
Volume 0.12M
Average 0.50M
CLNN Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Clene Inc.NASDAQ: CLNN
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 18.9% from a year ago
Property, plant & equipment (net) stood at $8.58M at the end of Q1 FY2026, down 18.9% from a year earlier and down 5.6% from the prior quarter. Over 3 fiscal years it compounded at -15.8% a year.
Context
- Property, plant & equipment (net) amounted to 39.6% of total assets at the end of Q1 FY2026, down 2.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -18.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 9.1M USD
- Year-over-year change
- -18.2%
- 4-year CAGR
- +1.9%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.1M | -18.2% |
| FY2024 | 2024-12-31 | 11.12M | -17.2% |
| FY2023 | 2023-12-31 | 13.43M | -11.9% |
| FY2022 | 2022-12-31 | 15.24M | +81.0% |
| FY2021 | 2021-12-31 | 8.42M | — |
Property, Plant & Equipment (Net) vs competitors
How CLNN compares with its peers on the latest reported figures
- CLNN's Mar 2026 property, plant & equipment (net) of $8.58M is the 5th highest of the 11 companies compared; the peer median is $6.89M.
- Its year-over-year change of -18.9% is the 6th highest of 11, against a peer median of -18.4%.
- Property, plant & equipment (net) amounts to 39.6% of total assets for CLNN, versus a peer median of 6.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $33.97M | -17.1% | -14.5% | 15.6% | |
| Mar 2026 | $28.25M | -19.7% | -16.6% | 11.2% | |
| Mar 2026 | $24.04M | -24.1% | +36.2% | 11.9% | |
| Mar 2026 | $11.52M | -10.4% | — | 5.1% | |
| Mar 2026 | $8.58M | -18.9% | -15.8% | 39.6% | |
| Mar 2026 | $8.42M | +26421.4% | -50.6% | 15.8% | |
| Mar 2026 | $5.35M | -39.7% | -29.8% | 5.2% | |
| Dec 2025 | $4.46M | +5.1% | -6.1% | 7.9% | |
| Mar 2026 | $1.25M | -44.3% | -9.6% | 0.5% | |
| Mar 2026 | $342.28K | +45.9% | +20.8% | 0.6% | |
WHWKWhitehawk Therapeutics Inc | Mar 2026 | $2K | -92.0% | -88.6% | 0.0% |
| Peer median (excluding CLNN) | $6.89M | -18.4% | -14.5% | 6.6% | |
Competitors are the stored peer set for CLNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 50.29M | 18.33M | 28.82M | 12.16M | 5.19M |
| Short-term Investments | 0 | 4.98M | 6.18M | 0 | 0 |
| Net Receivables | 1.61M | 2.97M | 1.34M | 391K | 590K |
| Inventory | 41K | 43K | 37K | 68K | 37K |
| Other Current Assets | 2.45M | 2.87M | 2.48M | 137K | 139K |
| Total Current Assets | 54.58M | 29.2M | 38.85M | 16.16M | 8.98M |
| Property, Plant & Equipment (Net) | 8.42M | 15.24M | 13.43M | 11.12M | 9.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 58K | 58K | 0 | 58K | 58K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 58K | 0 | 0 |
| Total Non-current Assets | 8.48M | 15.3M | 13.49M | 11.18M | 9.15M |
| Total Assets | 63.06M | 44.49M | 52.34M | 27.34M | 18.13M |
| Account Payables | 1.92M | 3.01M | 1.5M | 1.24M | 892K |
| Short-term Debt | 0 | 6.42M | 19.5M | 359K | 4.07M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 520K | 520K | 0 | 2.67M | 1.51M |
| Other Current Liabilities | 2.05M | 1.49M | 2.12M | 4.08M | 3.14M |
| Total Current Liabilities | 6.03M | 13.86M | 25.33M | 10.29M | 10.78M |
| Long-term Debt | 19.08M | 19.25M | 7.15M | 15.43M | 13.54M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 20.89M | 2.56M | 1.57M | 6.35M | 8.16M |
| Total Non-current Liabilities | 44.44M | 27.4M | 13.62M | 25.9M | 24.95M |
| Total Liabilities | 50.47M | 41.26M | 38.95M | 36.19M | 35.72M |
| Common Stock | 6K | 7K | 13K | 1K | 1K |
| Retained Earnings | (163.3M) | (193.22M) | (242.72M) | (282.12M) | (308.3M) |
| Accumulated OCI | 233K | 203K | 199K | 71K | 172K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 12.6M | 3.24M | 13.39M | (8.86M) | (17.59M) |
| Total Debt | 24.04M | 31.82M | 32.16M | 20.84M | 21.67M |
| Net Debt | (26.25M) | 13.49M | 3.34M | 8.69M | 16.48M |
Clene Inc.
NASDAQ:CLNN
Intrinsic Alpha fair value
Locked
Current Price
$3.66
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.